Currently, there are about 7000 identified rare diseases, together affecting 10% of the
population. However, fewer than 6% of all rare diseases have an approved treatment option …

The goal of this review is to provide further understanding of increased vascular stiffness
with aging, and how it contributes to the adverse effects of major human diseases …

Hutchinson–Gilford progeria syndrome (HGPS or progeria) is typically caused by a
dominant-negative C• G-to-T• A mutation (c. 1824 C> T; p. G608G) in LMNA, the gene that …

Lonafarnib (Zokinvy™) is an orally active farnesyltransferase inhibitor developed by Eiger
BioPharmaceuticals under license from Merck & Co. for the treatment of hepatitis D virus …

Protein lipid modification involves the attachment of hydrophobic groups to proteins via
ester, thioester, amide, or thioether linkages. In this review, the specific click chemical …

Hutchinson–Gilford progeria syndrome (HGPS) is a rare accelerated aging disorder
characterized by premature death from myocardial infarction or stroke. It is caused by de …

Abstract Aims Hutchinson-Gilford progeria syndrome (HGPS) is an accelerated ageing
syndrome associated with premature vascular disease and death due to heart attack and …

Hutchinson–Gilford progeria syndrome (HGPS) is a rare, invariably fatal childhood
premature aging disorder caused by a pre-messenger RNA (mRNA) splicing defect in the …

Hutchinson‐Gilford progeria syndrome (HGPS) is a rare accelerated aging disorder most
notably characterized by cardiovascular disease and premature death from myocardial …

Background: Hutchinson-Gilford progeria syndrome (HGPS) is a rare disorder characterized
by premature aging and death mainly because of myocardial infarction, stroke, or heart …